UNSPSC 51383309: Alclofenac

This classification denotes an anti-inflammatory agent with the molecular formula C11H11ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M9CP5H21N8, chemically known as benzeneacetic acid, 3-chloro-4-(2-propenyloxy)- but generally known as alclofenac, which bears US NIH Compound Identifier 30951. Alclofenac comes in many forms, including epoxide, monoethanolamine complex, and sodium. European Medicines Agency schedules Alclofenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05299MIG.

UNSPSC 51383309 Alclofenac is a Commodity code that nominally designates a specific anti-inflammatory pharmaceutical product, but the recent state and local opportunity posted under this code shows a mismatch: Seminole County, Florida's June 2026 solicitation (IFB60459723LAS) seeks Naloxone and Safe Drug Deactivation Systems, which fall outside the scope of Alclofenac and instead address opioid overdose response and drug disposal. The code shows minimal recent relevant activity aligned with its stated pharmaceutical scope.

The single posted opportunity names Seminole County as the issuing body and targets community health initiatives with quarterly deliveries of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually to the Seminole County Community Health Building in Sanford, Florida. The IFB closed July 26, 2023, with a two-year initial term and one-year renewal option. Bidders were required to submit unit costs, maintain workers' compensation and commercial general liability insurance, comply with E-Verify and drug-free workplace certification, and include all shipping and delivery costs in their proposals. The procurement was potentially funded through FEMA, introducing compliance requirements under the Clean Air Act and Federal Water Pollution Control Act. Geographic activity is limited to Florida based on available records, and no standout repeat buyers or broader state activity is evident.